Corvus Pharmaceuticals, Inc. (CRVS) Financials

CRVS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 239.3 million 13.9 million
March 31, 2026 253.2 million 12.5 million
Dec. 31, 2025 71.1 million 9.9 million
Sept. 30, 2025 80.5 million 8.7 million

CRVS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -16.0 million 2.6 million
March 31, 2026 -10.5 million 2.7 million
Dec. 31, 2025 -9.2 million 1.6 million
Sept. 30, 2025 -9.6 million 1.2 million

CRVS Net Income

No data available :(

CRVS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 215.2 million - 728000
March 31, 2026 236.7 million 406000 428000
Dec. 31, 2025 56.8 million - 534000
Sept. 30, 2025 65.7 million - 1.0 million

CRVS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 92.4 million
March 31, 2026 90.0 million
Dec. 31, 2025 79.7 million
Sept. 30, 2025 82.8 million

CRVS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 582000 16.0 million 3.3 million -
March 31, 2026 91000 11.2 million 3.7 million -
Dec. 31, 2025 25000 9.9 million 2.3 million -
Sept. 30, 2025 - 8.5 million 2.1 million -

CRVS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 29000
Dec. 31, 2025 - 26000
Sept. 30, 2025 - -

CRVS

Price: $14.89

52 week price:
4.05
26.95

Earnings Per Share: -0.64 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 47000

Ebitda: -12.7 million

Market Capitalization: 1.2 billion

Links: